ENTA
Income statement / Annual
Last year (2025), Enanta Pharmaceuticals, Inc.'s total revenue was $65.32 M,
a decrease of 3.42% from the previous year.
In 2025, Enanta Pharmaceuticals, Inc.'s net income was -$81.89 M.
See Enanta Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$65.32 M |
$67.64 M |
$79.20 M |
$86.16 M |
$97.07 M |
$122.47 M |
$205.20 M |
$206.63 M |
$102.81 M |
$88.27 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$65.32 M
|
$67.64 M
|
$79.20 M
|
$86.16 M
|
$97.07 M
|
$122.47 M
|
$205.20 M
|
$206.63 M
|
$102.81 M
|
$88.27 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$106.74 M
|
$131.48 M
|
$163.52 M
|
$164.52 M
|
$174.11 M
|
$136.76 M
|
$142.21 M
|
$94.86 M
|
$57.45 M
|
$40.46 M
|
| General & Administrative Expenses |
$43.93 M
|
$57.85 M
|
$52.89 M
|
$45.48 M
|
$32.54 M
|
$27.36 M
|
$26.25 M
|
$23.44 M
|
$20.75 M
|
$16.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$43.93 M
|
$57.85 M
|
$52.89 M
|
$45.48 M
|
$32.54 M
|
$27.36 M
|
$26.25 M
|
$23.44 M
|
$20.75 M
|
$16.97 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$150.67 M
|
$189.33 M
|
$216.41 M
|
$210.00 M
|
$206.65 M
|
$164.11 M
|
$168.46 M
|
$118.30 M
|
$78.20 M
|
$57.43 M
|
| Cost And Expenses |
$150.67 M
|
$189.33 M
|
$216.41 M
|
$210.00 M
|
$206.65 M
|
$164.11 M
|
$168.46 M
|
$118.30 M
|
$78.20 M
|
$57.43 M
|
| Interest Income |
$9.48 M
|
$14.77 M
|
$11.36 M
|
$1.57 M
|
$2.02 M
|
$6.47 M
|
$8.82 M
|
$0.00
|
$2.53 M
|
$1.74 M
|
| Interest Expense |
$7.68 M
|
$10.94 M
|
$5.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.85 M
|
$40.00 K
|
$45.00 K
|
| Depreciation & Amortization |
$5.09 M
|
$2.34 M
|
$2.37 M
|
$2.97 M
|
$3.33 M
|
$3.64 M
|
$3.26 M
|
$2.52 M
|
$2.14 M
|
$1.66 M
|
| EBITDA |
-$70.78 M |
-$104.51 M |
-$123.48 M |
-$119.22 M |
-$104.25 M |
-$38.00 M |
$40.00 M |
$90.85 M |
$26.75 M |
$32.50 M |
| EBITDA Ratio |
-1.08
|
-1.55
|
-1.56
|
-1.38
|
-1.07
|
-0.31
|
0.19
|
0.44
|
0.26
|
0.37
|
| Operating Income Ratio |
-1.31
|
-1.8
|
-1.73
|
-1.44
|
-1.13
|
-0.34
|
0.18
|
0.43
|
0.24
|
0.35
|
| Total Other Income/Expenses Net |
$1.80 M
|
$3.90 M
|
$6.21 M
|
$1.66 M
|
$1.99 M
|
$6.62 M
|
$8.82 M
|
$4.79 M
|
$2.33 M
|
$1.72 M
|
| Income Before Tax |
-$83.55 M
|
-$117.79 M
|
-$131.00 M
|
-$122.19 M
|
-$107.58 M
|
-$35.02 M
|
$45.56 M
|
$93.12 M
|
$26.95 M
|
$32.56 M
|
| Income Before Tax Ratio |
-1.28
|
-1.74
|
-1.65
|
-1.42
|
-1.11
|
-0.29
|
0.22
|
0.45
|
0.26
|
0.37
|
| Income Tax Expense |
-$1.66 M
|
-$1.74 M
|
$2.82 M
|
-$433.00 K
|
-$28.58 M
|
$1.15 M
|
-$826.00 K
|
$21.17 M
|
$9.24 M
|
$10.89 M
|
| Net Income |
-$81.89 M
|
-$116.05 M
|
-$133.82 M
|
-$121.76 M
|
-$79.00 M
|
-$36.17 M
|
$46.38 M
|
$71.96 M
|
$17.71 M
|
$21.67 M
|
| Net Income Ratio |
-1.25
|
-1.72
|
-1.69
|
-1.41
|
-0.81
|
-0.3
|
0.23
|
0.35
|
0.17
|
0.25
|
| EPS |
-3.84 |
-5.48 |
-6.38 |
-5.91 |
-3.92 |
-1.81 |
2.37 |
3.48 |
0.93 |
1.14 |
| EPS Diluted |
-3.84 |
-5.48 |
-6.38 |
-5.91 |
-3.92 |
-1.81 |
2.21 |
3.48 |
0.91 |
1.13 |
| Weighted Average Shares Out |
$21.34 M
|
$21.16 M
|
$20.97 M
|
$20.60 M
|
$20.17 M
|
$19.94 M
|
$19.58 M
|
$20.65 M
|
$19.07 M
|
$18.93 M
|
| Weighted Average Shares Out Diluted |
$21.34 M
|
$21.16 M
|
$20.97 M
|
$20.60 M
|
$20.17 M
|
$19.94 M
|
$20.97 M
|
$20.65 M
|
$19.41 M
|
$19.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
